Paul C. Langley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul C. Langley has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
J. Sanford Schwartz
1 shared publicationJames McKenney
1 shared publicationJoel W. Hay
1 shared publicationM H Smith
1 shared publicationSidney C. Smith
1 shared publication- Stephen K. Tyring
The University of Texas Medical Branch at Galveston
1 shared publication
Latest Publications
- 1 January 1999
- Vol. 5 (1) , 69-77
The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts.
External genital warts are one of the fastest growing sexually transmitted diseases in the United States today. Two forms of therapy are available: provider-administered and patient-applied. In the most widely used provider-administered ablative therapies, sustained clearance rates range from 18.5% to 40.1%. With nonablative, patient-applied therapies, which are typically more acceptable to patients, sustained clearance rates range from 19.6% with podofilox gel to 44.0% with imiquimod cream. The purpose of this study, given the range of therapies available, their cost differences, and clinical trial-reported differences in rates of sustained clearance, is to determine which therapy modalities, from the providers' perspective, are the most cost effective and which are likely to be the most acceptable to the patient population. We consider the cost effectiveness of the two patient-applied therapies as first-line therapy followed by provider-administered ablative treatment as second-line therapy. A decision-analytic model framework is developed, with data drawn both from clinical trials and from previously published studies. When considering a two-stage therapy model, with an average sustained clearance rate of 30% assumed for provider-administered ablative therapies, estimated costs per sustained cleared patient are $1265 for patients initially treated with imiquimod and $1304 for patients initially treated with podofilox gel. Initial treatment with imiquimod is the preferred intervention option as it yields a 39% greater sustained clearance rate than podofilox gel while being 3% less costly per successful outcome.
- 1 January 1999
- Vol. 5 (1) , 69-77
The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts.
External genital warts are one of the fastest growing sexually transmitted diseases in the United States today. Two forms of therapy are available: provider-administered and patient-applied. In the most widely used provider-administered ablative therapies, sustained clearance rates range from 18.5% to 40.1%. With nonablative, patient-applied therapies, which are typically more acceptable to patients, sustained clearance rates range from 19.6% with podofilox gel to 44.0% with imiquimod cream. The purpose of this study, given the range of therapies available, their cost differences, and clinical trial-reported differences in rates of sustained clearance, is to determine which therapy modalities, from the providers' perspective, are the most cost effective and which are likely to be the most acceptable to the patient population. We consider the cost effectiveness of the two patient-applied therapies as first-line therapy followed by provider-administered ablative treatment as second-line therapy. A decision-analytic model framework is developed, with data drawn both from clinical trials and from previously published studies. When considering a two-stage therapy model, with an average sustained clearance rate of 30% assumed for provider-administered ablative therapies, estimated costs per sustained cleared patient are $1265 for patients initially treated with imiquimod and $1304 for patients initially treated with podofilox gel. Initial treatment with imiquimod is the preferred intervention option as it yields a 39% greater sustained clearance rate than podofilox gel while being 3% less costly per successful outcome.
- 1 January 1999
- Published by Springer Nature in PharmacoEconomics
- Vol. 16 (3) , 211-224
Formulary Submission Guidelines for Blue Cross and Blue Shield of Colorado and Nevada
- 1 January 1999
- Published by Springer Nature in PharmacoEconomics
- Vol. 16 (3) , 211-224
Formulary Submission Guidelines for Blue Cross and Blue Shield of Colorado and Nevada
- 1 November 1998
- Published by Elsevier in Value in Health
- Vol. 1 (4) , 208-211
Criteria for the Economic Evaluation of Lipid Studies in Health Systems
- 1 November 1998
- Published by Elsevier in Value in Health
- Vol. 1 (4) , 208-211
Criteria for the Economic Evaluation of Lipid Studies in Health Systems
- Open Access
- 1 November 1998
- Published by Elsevier in Value in Health
- Vol. 1 (4) , 243-250
From Research into Practice: How Should Healthcare Organizations/Governments Decide about Lipid Therapy and Who Will Pay? Reactor Panel and Open Forum
- 1 November 1998
- Published by Elsevier in Value in Health
- Vol. 1 (4) , 243-250
Open AccessFrom Research into Practice: How Should Healthcare Organizations/Governments Decide about Lipid Therapy and Who Will Pay? Reactor Panel and Open Forum